Page 67 - Demo

ANALESRANFwww.analesranf.com58. DNAtrix I. A Phase 1b, Randomized, Multicenter, Open-label Study of a ConditionallyReplicative Adenovirus (DNX-2401) andInterferon Gamma (IFN-%u03b3) for RecurrentGlioblastoma or Gliosarcoma (TARGET-I)2018 [Available from:https://clinicaltrials.gov/study/NCT0219716959. MediGene. An Open-Label Phase Ib/II Study ofthe Safety, Tolerability and Efficacy of G207,a Genetically Engineered Herpes SimplexType-1 Virus, Administered Intracerebrally toPatients With Recurrent Malignant Glioma2005 [Available from:https://clinicaltrials.gov/study/NCT00028158 60. Phase I/IIa Study of Intratumoral/Intracerebralor Intravenous/Intracerebral Administrationof Parvovirus H-1 (ParvOryx) in Patients WithProgressive Primary or RecurrentGlioblastoma Multiforme 2022 [Availablefrom: https://clinicaltrials.gov/study/NCT0130143061. Clinica-Universidad-Navarra. Phase I Trial ofCombination of DNX-2401 (Formerly NamedDelta-24-RGD) Oncolytic Adenovirus With aShort Course of Temozolomide for Treatment ofGlioblastoma at First Recurrent 2017 [Available from:https://clinicaltrials.gov/study/NCT01956734 62. Friedman G. Phase I Clinical Trial of HSV G207Alone or With a Single Radiation Dose inChildren With Recurrent Supratentorial BrainTumors 2024 [Available from:https://clinicaltrials.gov/study/NCT02457845 .Inmunoterapia contra glioblastoma multiformeLuc%u00eda S%u00e1nchez Prieto y %u00c1ngel Cuesta Mart%u00ednez 65 An. R. Acad. Farm.vol. 91. n%u00ba 1 (2025) %u00b7 pp. 45-66Si desea citar nuestro art%u00edculo:Inmunoterapia en acci%u00f3n: estrategiasinnovadoras contra el glioblastomamultiformeLuc%u00eda S%u00e1nchez Prieto y %u00c1ngel Cuesta Mart%u00ednezAn Real Acad Farm (Internet).An. Real Acad. Farm.Vol. 91. n%u00ba 1 (2025) %u00b7 pp. 45-65DOI:http://dx.doi.org/10.53519/analesranf.2025.91.01.02